Business Description
Faron Pharmaceuticals Oy
ISIN : FI4000153309
Total Employee Number:
33Description
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.5 | |||||
Equity-to-Asset | -1.08 | |||||
Debt-to-Equity | -1.33 | |||||
Debt-to-EBITDA | -0.97 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 17.2 | |||||
3-Year EPS without NRI Growth Rate | 19.7 | |||||
3-Year FCF Growth Rate | 22.5 | |||||
3-Year Book Growth Rate | -0.5 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 31.78 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 78.61 | |||||
9-Day RSI | 65.08 | |||||
14-Day RSI | 57.93 | |||||
3-1 Month Momentum % | -0.58 | |||||
6-1 Month Momentum % | -73.66 | |||||
12-1 Month Momentum % | -78.39 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.84 | |||||
Quick Ratio | 0.84 | |||||
Cash Ratio | 0.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.7 | |||||
Shareholder Yield % | -24.08 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -178.96 | |||||
ROIC % | -227.5 | |||||
3-Year ROIIC % | 105.92 | |||||
ROC (Joel Greenblatt) % | -10793.27 | |||||
ROCE % | -888.64 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -4.27 | |||||
EV-to-EBITDA | -4.32 | |||||
EV-to-Forward-EBITDA | -6.53 | |||||
EV-to-Forward-Revenue | 744 | |||||
EV-to-FCF | -6.14 | |||||
Earnings Yield (Greenblatt) % | -23.42 | |||||
FCF Yield % | -18.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Faron Pharmaceuticals Oy Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.221 | ||
| Beta | 2.5129 | ||
| 3-Year Sharpe Ratio | -0.17 | ||
| 3-Year Sortino Ratio | -0.23 | ||
| Volatility % | 73.57 | ||
| 14-Day RSI | 57.93 | ||
| 14-Day ATR (€) | 0.012015 | ||
| 20-Day SMA (€) | 0.4837 | ||
| 12-1 Month Momentum % | -78.39 | ||
| 52-Week Range (€) | 0.4355 - 2.535578 | ||
| Shares Outstanding (Mil) | 202.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Faron Pharmaceuticals Oy Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Faron Pharmaceuticals Oy Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-26 | In 51 days | ||
| Second quarter earnings results for 2026 | 2026-08-26 | In 51 days | ||
| Guidance call for 2026 | 2026-05-12 18:45 | 0.47 (+0.00%) | ||
| General meeting for 2025 | 2026-05-04 10:00 | 0.44 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-04 09:00 | 0.55 (+0.00%) | ||
| Annual report for 2025 | 2026-03-04 | 0.55 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 0.55 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-27 09:00 | 2.43 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-27 | 2.43 (+0.00%) | ||
| General meeting for 2024 | 2025-03-21 10:00 | 2.16 (+0.00%) |
Show
Entries
Faron Pharmaceuticals Oy Frequently Asked Questions
What is Faron Pharmaceuticals Oy(FRA:4FR)'s stock price today?
The current price of FRA:4FR is €0.51. The 52 week high of FRA:4FR is €2.54 and 52 week low is €0.44.
When is next earnings date of Faron Pharmaceuticals Oy(FRA:4FR)?
The next earnings date of Faron Pharmaceuticals Oy(FRA:4FR) is 2026-08-26.
Does Faron Pharmaceuticals Oy(FRA:4FR) pay dividends? If so, how much?
Faron Pharmaceuticals Oy(FRA:4FR) does not pay dividend.
Press Release
Articles on Faron Pharmaceuticals Oy
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers